Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Policy Power Challenged In House Questions On Untitled Letters

This article was originally published in The Pink Sheet Daily

Executive Summary

Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours.


Related Content

FDA’s Untitled Letter Posting Driven By ‘Significant Public Interest,’ Not Stock Market
Biosimilar Naming, Interchangeability Policies Must Be Done Soon, House Tells FDA
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA Off-Label Citations Disappear In Post-Caronia Enforcement Letters
Warning For Facebook “Likes” Reflects FDA Social Media Approach
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes
GMP Closeout "Carrots" Sprout; Baxter Receives First, But FDA Is Subdued
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts